Fasudil, a clinically safe ROCK inhibitor, decreases disease burden in a Cbl/Cbl-b deficiency-driven murine model of myeloproliferative disorders.

about

Fasudil, a clinically safe ROCK inhibitor, decreases disease burden in a Cbl/Cbl-b deficiency-driven murine model of myeloproliferative disorders.

Item

http://www.wikidata.org/entity/Q41378115

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Fasudil, a clinically safe ROC ...... myeloproliferative disorders.

@en

type

Item

label

Fasudil, a clinically safe ROC ...... myeloproliferative disorders.

@en

prefLabel

Fasudil, a clinically safe ROC ...... myeloproliferative disorders.

@en

P1476

Fasudil, a clinically safe ROC ...... myeloproliferative disorders.

@en

P2093

Basem M William

http://www.w3.org/2001/XMLSchema#string

Dan Feng

http://www.w3.org/2001/XMLSchema#string

Hamid Band

http://www.w3.org/2001/XMLSchema#string

Matthew A Storck

http://www.w3.org/2001/XMLSchema#string

Scott Nadeau

http://www.w3.org/2001/XMLSchema#string

Vimla Band

http://www.w3.org/2001/XMLSchema#string

Wei An

http://www.w3.org/2001/XMLSchema#string

P2860

Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases

Rho kinase proteins--pleiotropic modulators of cell survival and apoptosis

A gain-of-function mutation of JAK2 in myeloproliferative disorders

Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy

Cbl and human myeloid neoplasms: the Cbl oncogene comes of age.

Systematic assessment and meta-analysis of the efficacy and safety of fasudil in the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage.

Rapidly fatal myeloproliferative disorders in mice with deletion of Casitas B-cell lymphoma (Cbl) and Cbl-b in hematopoietic stem cells.

Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.

Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL.

Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension.

P304

218-224

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1179/1607845415Y.0000000031

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Bhopal C Mohapatra

P577

2015-07-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26177294

http://www.w3.org/2001/XMLSchema#string

P932

5555218

http://www.w3.org/2001/XMLSchema#string